Turgay Yılmaz
Research Subjects
Research Interests
Turgay Yılmaz has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Adem Kose
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Inonu University, Malatya, Turkey
1 shared publication - Ahmet Tahiroğlu1 shared publication
- Ahmet Özcan
Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine Suleyman Demirel University Isparta Türkiye
1 shared publication - Aleyna Doyran1 shared publication
- Ayhan Levent1 shared publication
- Aykut Yaman1 shared publication
Latest Publications
- 19 November 2026
- Published by Academician Publishing
- p. 251-258
Monoklonal Antikor Tedavisi Sonrası İzole Akut Solunum Sıkıntısı Sendromu Gelişen Meme Kanserli Olgu
- 19 November 2026
- Published by Academician Publishing
- p. 251-258
Monoklonal Antikor Tedavisi Sonrası İzole Akut Solunum Sıkıntısı Sendromu Gelişen Meme Kanserli Olgu
- 19 November 2026
- Published by Academician Publishing
Olgular Eşliğinde Genel Dahiliye III
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1) , 9096871
Clinical and Histopathological Correlation of Quantitative HBsAg Levels in Chronic Hepatitis B
Objective: This study is aimed at comparing different clinical forms of chronic hepatitis B (CHB) infection (HBeAg‐negative chronic HBV infection and HBeAg‐positive and HBeAg‐negative CHB patients) and evaluate their demographic, laboratory, virological, and histopathological characteristics, as well as investigate the relationship between quantitative HBsAg (qHBsAg) levels and these parameters. Materials and Methods: This prospective study included a total of 307 patients, comprising 142 HBeAg‐negative chronic HBV infection and 165 CHB patients (39 HBeAg‐positive and 126 HBeAg‐negative). Patient data, including age, sex, ALT, AST, GGT, ALP, total bilirubin, HBV DNA, and qHBsAg levels, were recorded. Additionally, liver biopsy was performed in 111 cases (31 HBeAg‐positive and 80 HBeAg‐negative), and histological activity index (HAI) and fibrosis staging (ISHAK score) were evaluated. Results: No significant differences were observed between HBeAg‐negative chronic HBV infection and CHB patients in age and sex distribution. In the CHB group, ALT and HBV DNA levels were significantly higher ( p = 0.014 and p = 0.025, respectively). Among CHB patients, HBeAg‐positive patients had significantly lower qHBsAg levels than HBeAg‐negative patients (1805 vs. 4028 IU/mL, p < 0.001). Histopathological evaluations showed no significant association between qHBsAg levels and fibrosis severity (ISHAK score > 2) or necroinflammatory activity (HAI > 6). ROC analysis confirmed the limited diagnostic value of qHBsAg for advanced fibrosis (AUC 0.511, 95% CI 0.454–0.569). In HBeAg‐positive patients, a weak negative correlation was found between qHBsAg and HBV DNA levels ( r = –0.388, p = 0.015). Discussion: Our study demonstrated variability in laboratory findings across different forms of CHB. Notably, HBeAg‐positive patients exhibited high HBV DNA levels alongside low qHBsAg levels. The limited efficacy of qHBsAg as a fibrosis marker suggests caution in its clinical use. These findings underscore the importance of considering multiple parameters in assessing liver damage.
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1) , 9096871
Open AccessClinical and Histopathological Correlation of Quantitative HBsAg Levels in Chronic Hepatitis B
Objective: This study is aimed at comparing different clinical forms of chronic hepatitis B (CHB) infection (HBeAg‐negative chronic HBV infection and HBeAg‐positive and HBeAg‐negative CHB patients) and evaluate their demographic, laboratory, virological, and histopathological characteristics, as well as investigate the relationship between quantitative HBsAg (qHBsAg) levels and these parameters. Materials and Methods: This prospective study included a total of 307 patients, comprising 142 HBeAg‐negative chronic HBV infection and 165 CHB patients (39 HBeAg‐positive and 126 HBeAg‐negative). Patient data, including age, sex, ALT, AST, GGT, ALP, total bilirubin, HBV DNA, and qHBsAg levels, were recorded. Additionally, liver biopsy was performed in 111 cases (31 HBeAg‐positive and 80 HBeAg‐negative), and histological activity index (HAI) and fibrosis staging (ISHAK score) were evaluated. Results: No significant differences were observed between HBeAg‐negative chronic HBV infection and CHB patients in age and sex distribution. In the CHB group, ALT and HBV DNA levels were significantly higher ( p = 0.014 and p = 0.025, respectively). Among CHB patients, HBeAg‐positive patients had significantly lower qHBsAg levels than HBeAg‐negative patients (1805 vs. 4028 IU/mL, p < 0.001). Histopathological evaluations showed no significant association between qHBsAg levels and fibrosis severity (ISHAK score > 2) or necroinflammatory activity (HAI > 6). ROC analysis confirmed the limited diagnostic value of qHBsAg for advanced fibrosis (AUC 0.511, 95% CI 0.454–0.569). In HBeAg‐positive patients, a weak negative correlation was found between qHBsAg and HBV DNA levels ( r = –0.388, p = 0.015). Discussion: Our study demonstrated variability in laboratory findings across different forms of CHB. Notably, HBeAg‐positive patients exhibited high HBV DNA levels alongside low qHBsAg levels. The limited efficacy of qHBsAg as a fibrosis marker suggests caution in its clinical use. These findings underscore the importance of considering multiple parameters in assessing liver damage.